For patients with disseminated malignant melanoma, fotemustine seems to offer some advantage in terms of response rate, safety and time to brain metastasis compared to dacarbazine, according to results reported at the European Society for Medical Oncology conference.
“Dacarbazine is considered the standard of care, but it is far away from being a gold standard,” Dr. Axel Hauschild from the Universitats-Hautklinik in Kiel, Germany told attendees.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!